CN102421742B - 3-戊基苯乙酸的盐及其药物用途 - Google Patents
3-戊基苯乙酸的盐及其药物用途 Download PDFInfo
- Publication number
- CN102421742B CN102421742B CN201080020140.5A CN201080020140A CN102421742B CN 102421742 B CN102421742 B CN 102421742B CN 201080020140 A CN201080020140 A CN 201080020140A CN 102421742 B CN102421742 B CN 102421742B
- Authority
- CN
- China
- Prior art keywords
- salt
- disease
- kidney
- illness
- experimenter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NBSIBRDOKQUIGC-UHFFFAOYSA-N CCCCCc1cccc(CC(N=O)=O)c1 Chemical compound CCCCCc1cccc(CC(N=O)=O)c1 NBSIBRDOKQUIGC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
Abstract
Description
骨髓红细胞数(106) | 红细胞(109) | |
对照 | 20.3 | 7.1 |
环磷酰胺 | 8.1 | 5.7 |
化合物I | 11.5 | 7.0 |
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17521509P | 2009-05-04 | 2009-05-04 | |
US61/175,215 | 2009-05-04 | ||
PCT/CA2010/000691 WO2010127448A1 (en) | 2009-05-04 | 2010-05-03 | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102421742A CN102421742A (zh) | 2012-04-18 |
CN102421742B true CN102421742B (zh) | 2014-08-06 |
Family
ID=43049882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080020140.5A Active CN102421742B (zh) | 2009-05-04 | 2010-05-03 | 3-戊基苯乙酸的盐及其药物用途 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8637574B2 (zh) |
EP (1) | EP2427417B1 (zh) |
JP (1) | JP5844251B2 (zh) |
KR (1) | KR20120090011A (zh) |
CN (1) | CN102421742B (zh) |
AU (1) | AU2010244938A1 (zh) |
BR (1) | BRPI1015118A2 (zh) |
CA (1) | CA2761061A1 (zh) |
DK (1) | DK2427417T3 (zh) |
ES (1) | ES2441800T3 (zh) |
HK (1) | HK1169379A1 (zh) |
MX (1) | MX2011011756A (zh) |
PL (1) | PL2427417T3 (zh) |
PT (1) | PT2427417E (zh) |
TW (1) | TWI458481B (zh) |
WO (1) | WO2010127448A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105143170A (zh) * | 2013-03-15 | 2015-12-09 | 普罗米蒂克生物科学公司 | 用于治疗肺纤维化、肝纤维化、皮肤纤维化和心脏纤维化的经取代的芳族化合物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2427416T3 (en) | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
EP3443957B1 (en) * | 2010-10-27 | 2020-11-25 | Liminal Biosciences Limited | Compounds and compositions for the treatment of cancer |
US20130225683A1 (en) * | 2010-10-27 | 2013-08-29 | Prometic Biosciences Inc. | Compounds and Pharmaceutical Compositions for Uses in Diabetes |
TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
CN106999456B (zh) * | 2014-10-10 | 2020-07-10 | 里米诺生物科学有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
WO2016074068A1 (en) * | 2014-11-12 | 2016-05-19 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
WO2020113340A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal Biosciences Limited | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
CN112441916A (zh) * | 2019-08-29 | 2021-03-05 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
EP4051659A1 (en) * | 2019-10-31 | 2022-09-07 | Teva Pharmaceuticals International GmbH | Solid state forms of fezagepras and process for preparation thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
US3894080A (en) * | 1970-05-05 | 1975-07-08 | Rorer Inc William H | Phenylacetic acids |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3385887A (en) * | 1961-02-02 | 1968-05-28 | Boots Pure Drug Co Ltd | 4-isobutylphenylacetic acid |
WO2005010202A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS |
DK2427416T3 (en) * | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
-
2010
- 2010-05-03 US US13/318,252 patent/US8637574B2/en active Active
- 2010-05-03 DK DK10771941.1T patent/DK2427417T3/da active
- 2010-05-03 AU AU2010244938A patent/AU2010244938A1/en not_active Abandoned
- 2010-05-03 JP JP2012508864A patent/JP5844251B2/ja not_active Expired - Fee Related
- 2010-05-03 BR BRPI1015118A patent/BRPI1015118A2/pt not_active Application Discontinuation
- 2010-05-03 PL PL10771941T patent/PL2427417T3/pl unknown
- 2010-05-03 WO PCT/CA2010/000691 patent/WO2010127448A1/en active Application Filing
- 2010-05-03 EP EP10771941.1A patent/EP2427417B1/en active Active
- 2010-05-03 MX MX2011011756A patent/MX2011011756A/es active IP Right Grant
- 2010-05-03 CA CA2761061A patent/CA2761061A1/en not_active Abandoned
- 2010-05-03 KR KR1020117028776A patent/KR20120090011A/ko not_active Application Discontinuation
- 2010-05-03 TW TW099114043A patent/TWI458481B/zh active
- 2010-05-03 CN CN201080020140.5A patent/CN102421742B/zh active Active
- 2010-05-03 ES ES10771941.1T patent/ES2441800T3/es active Active
- 2010-05-03 PT PT107719411T patent/PT2427417E/pt unknown
-
2012
- 2012-10-15 HK HK12110169.0A patent/HK1169379A1/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
US3894080A (en) * | 1970-05-05 | 1975-07-08 | Rorer Inc William H | Phenylacetic acids |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105143170A (zh) * | 2013-03-15 | 2015-12-09 | 普罗米蒂克生物科学公司 | 用于治疗肺纤维化、肝纤维化、皮肤纤维化和心脏纤维化的经取代的芳族化合物 |
CN105143170B (zh) * | 2013-03-15 | 2019-11-08 | 普罗米蒂克医药Smt有限公司 | 用于治疗肺纤维化、肝纤维化、皮肤纤维化和心脏纤维化的经取代的芳族化合物 |
Also Published As
Publication number | Publication date |
---|---|
HK1169379A1 (zh) | 2013-01-25 |
MX2011011756A (es) | 2012-01-25 |
DK2427417T3 (da) | 2014-01-20 |
KR20120090011A (ko) | 2012-08-16 |
JP2012526053A (ja) | 2012-10-25 |
TWI458481B (zh) | 2014-11-01 |
TW201043226A (en) | 2010-12-16 |
BRPI1015118A2 (pt) | 2016-04-12 |
WO2010127448A1 (en) | 2010-11-11 |
CA2761061A1 (en) | 2010-11-11 |
US8637574B2 (en) | 2014-01-28 |
ES2441800T3 (es) | 2014-02-06 |
EP2427417A1 (en) | 2012-03-14 |
JP5844251B2 (ja) | 2016-01-13 |
CN102421742A (zh) | 2012-04-18 |
US20120095102A1 (en) | 2012-04-19 |
EP2427417B1 (en) | 2013-10-09 |
PT2427417E (pt) | 2014-01-13 |
EP2427417A4 (en) | 2012-09-26 |
PL2427417T3 (pl) | 2014-03-31 |
AU2010244938A1 (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102421742B (zh) | 3-戊基苯乙酸的盐及其药物用途 | |
CN102438975A (zh) | 取代的芳香化合物及其药物用途 | |
CN100430048C (zh) | 治疗下泌尿道症状的α-2-δ配体 | |
CN104039775A (zh) | Atp-结合盒转运蛋白的调节剂 | |
CN101243096A (zh) | 抗病毒化合物 | |
CN103848810A (zh) | 鲁顿酪氨酸激酶抑制剂 | |
CN104837503A (zh) | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 | |
CN114007621A (zh) | 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂 | |
CN104902930A (zh) | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 | |
WO2011156003A2 (en) | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | |
JPS6154A (ja) | 抗アレルギー、抗喘息及び抗炎症剤としてのフエニルアセトアミド | |
CN103298777A (zh) | 苯基酮羧酸盐化合物和其药学用途 | |
CN115192573A (zh) | 盐酸去亚甲基小檗碱在制备治疗肺纤维化药物中的应用 | |
JP2022533251A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
UA61955C2 (en) | Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy | |
WO2022111493A1 (zh) | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 | |
TW201311636A (zh) | 用於治療自體免疫發炎疾病之化合物 | |
US20200360331A1 (en) | COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES | |
CN101962323B (zh) | 2-丙烯酰x基-3-取代苯基丙酸类化合物及其用途 | |
US20220265593A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases | |
WO2022141328A1 (zh) | 硫代咪唑烷酮药物在治疗covid-19疾病中的用途 | |
RU2589258C1 (ru) | Средство пептидной структуры, ингибирующее дипептидилпептидазу-4, и фармацевтическая композиция на его основе | |
CN104434850A (zh) | 一种含有阿德福韦酯的口服固体药物组合物 | |
CN112979705A (zh) | 核苷酸类似物化合物及其盐、制备方法及其药物用途 | |
JP3981739B2 (ja) | 抗癌剤、癌細胞の増殖を抑制する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169379 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169379 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160725 Address after: cambridge Patentee after: The general Midike Pharmaceutical Co. Ltd. SMT Address before: Quebec Patentee before: Prometic Biosciences Inc. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof Effective date of registration: 20181016 Granted publication date: 20140806 Pledgee: Structured Alfa limited partnership Pledgor: The general Midike Pharmaceutical Co. Ltd. SMT Registration number: 2018990000969 |